Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 9:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,377 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pancreas Tumor Clear all
Completed Phase 1 Interventional

Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

NCT02345408
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CCX872-B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

NCT02004262
View directory record Official record
Conditions
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Interventions
GVAX Pancreas Vaccine, CRS-207, Chemotherapy, cyclophosphamide
Biological · Drug
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 21, 2026, 9:52 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

NCT00426127
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Docetaxel, Liposomal Doxorubicin, Enoxaparin
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 1 Interventional

Chemoimmunotherapy and Radiation in Pancreatic Cancer

NCT01903083
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm
Interventions
Tadalafil, Gemcitabine, Radiation, Pancreaticoduodenectomy
Drug · Radiation · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 1 Interventional Results available

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

NCT01296763
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Irinotecan, Cisplatin, Olaparib (for levels 1 and 5), Olaparib (for dose level 2), Mitomycin-C
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Not applicable Interventional Results available

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

NCT02241187
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PEGPH20, Cetuximab, DW & DCE-MRI, blood draws
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 21, 2026, 9:52 PM EDT
Recruiting Phase 1 Interventional

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT07454642
View directory record Official record
Conditions
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions
AVA6103
Drug
Lead sponsor
Avacta Life Sciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Grand Rapids, Michigan • Irving, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

NCT04426669
View directory record Official record
Conditions
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
Interventions
Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Not applicable Interventional Results available

Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking

NCT00790569
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
nicotine, varenicline, placebo
Drug · Other
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

NCT02178436
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
Interventions
gemcitabine hydrochloride, Selinexor, Pharmacological Study, Laboratory Biomarker Analysis, Nab paclitaxel
Drug · Other
Lead sponsor
Mohammed Najeeb Al Hallak
Other
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Detroit, Michigan • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

NCT02191761
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Hepatic Cancer, Pancreatic Cancer
Interventions
SM04755
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 1 Interventional

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00039403
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 21, 2026, 9:52 PM EDT
Terminated Phase 3 Interventional

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

NCT00014651
View directory record Official record
Conditions
Pancreatic Cancer, Perioperative/Postoperative Complications
Interventions
vapreotide, conventional surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
18
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Sep 21, 2026, 9:52 PM EDT
Terminated No phase listed Observational

Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy

NCT03407040
View directory record Official record
Conditions
Gastrointestinal Cancers, Breast Cancer, Pancreatic Cancer, Melanoma, Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

NCT01869725
View directory record Official record
Conditions
Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor, Somatostatinoma
Interventions
gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide, computed tomography, contrast-enhanced magnetic resonance imaging
Drug · Procedure · Radiation
Lead sponsor
Sue O'Dorisio
Other
Eligibility
2 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 21, 2026, 9:52 PM EDT
Withdrawn No phase listed Observational

A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer

NCT03707444
View directory record Official record
Conditions
Cancer Pancreas, Pain Syndrome, Cancer Related Pain
Interventions
Scrambler Therapy Device
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 3 Interventional Results available

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

NCT02923921
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pegilodecakin, FOLFOX
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
57
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

NCT02195232
View directory record Official record
Conditions
Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
Interventions
Isoquercetin
Drug
Lead sponsor
Jeffrey Zwicker, MD
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • West Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 21, 2026, 9:52 PM EDT
Recruiting No phase listed Observational

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

NCT00899626
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Precancerous Condition
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2045
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Recruiting Phase 2 Interventional

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317
View directory record Official record
Conditions
Adenocarcinoma, Carcinoma, Pancreatic Ductal
Interventions
Relacorilant, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633
View directory record Official record
Conditions
Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
[18F]FPyQCP
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 1 Interventional

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

NCT04050085
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Nivolumab, Radiation Therapy, TLR9 Agonist SD-101
Biological · Radiation · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 21, 2026, 9:52 PM EDT
Active, not recruiting Phase 1 Interventional

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

NCT05057715
View directory record Official record
Conditions
Pancreatic Cancer, Serous Ovarian Cancer
Interventions
VCN-01, huCART-meso Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 2 Interventional

Preop Chemoradiation Resectable Pancreas

NCT00336648
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Avastin (Bevacizumab), Gemcitabine, Radiation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 21, 2026, 9:52 PM EDT